Payment overview · 2025
General Payments
$37.54
2 reported records · 2 companies
Healthcare provider profile · identity verified
Yissel Jorge Puig
Allopathic & Osteopathic Physicians|Internal Medicine · HIALEAH, FL · NPI 1003198144
Verified facts
What the public records show
CMS Open Payments records show Yissel Jorge Puig received $37.54 in general payments during 2025 across 2 reported records.
GlaxoSmithKline, LLC. accounted for 60.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Shingrix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.72 | 60.5% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $14.82 | 39.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $37.54 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.72 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $14.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 39 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
39 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 988 | 203 |
| Atorvastatin Calcium | Atorvastatin Calcium | 802 | 263 |
| Omeprazole | Omeprazole | 737 | 230 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 718 | 235 |
| Losartan Potassium | Losartan Potassium | 631 | 174 |
| Levothyroxine Sodium | Levothyroxine Sodium | 461 | 134 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 460 | 106 |
| Metformin Hcl | Metformin Hcl | 452 | 125 |
| Furosemide | Furosemide | 445 | 140 |
| Warfarin Sodium | Warfarin Sodium | 443 | suppressed |
| Lisinopril | Lisinopril | 431 | 120 |
| Metoprolol Tartrate | Metoprolol Tartrate | 421 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 411 | 113 |
| Xarelto | Rivaroxaban | 325 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 297 | 97 |
| Glipizide | Glipizide | 291 | 82 |
| Hydrochlorothiazide | Hydrochlorothiazide | 280 | 91 |
| Famotidine | Famotidine | 266 | 87 |
| Carvedilol | Carvedilol | 236 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 229 | 84 |
| Fluticasone Propionate | Fluticasone Propionate | 223 | 117 |
| Metoprolol Succinate | Metoprolol Succinate | 222 | 66 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 217 | 53 |
| Folic Acid | Folic Acid | 215 | 66 |
| Sildenafil Citrate | Sildenafil Citrate | 215 | 41 |
| Montelukast Sodium | Montelukast Sodium | 211 | 63 |
| Glipizide Er | Glipizide | 210 | 65 |
| Hydrocortisone | Hydrocortisone | 191 | 61 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 184 | 51 |
| Simvastatin | Simvastatin | 179 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 178 | 63 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 152 | 67 |
| Alendronate Sodium | Alendronate Sodium | 151 | 55 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 142 | 70 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 132 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 128 | 64 |
| Trazodone Hcl | Trazodone Hcl | 124 | 35 |
| Buspirone Hcl | Buspirone Hcl | 120 | 49 |
| Allopurinol | Allopurinol | 118 | 36 |
| Ibandronate Sodium | Ibandronate Sodium | 115 | 51 |
| Temazepam | Temazepam | 114 | 15 |
| Donepezil Hcl | Donepezil Hcl | 110 | 38 |
| Finasteride | Finasteride | 104 | 30 |
| Metformin Hcl Er | Metformin Hcl | 104 | 36 |
| Fenofibrate | Fenofibrate | 103 | 34 |
| Dapagliflozin | Dapagliflozin Propanediol | 101 | 24 |
| Memantine Hcl | Memantine Hcl | 100 | 32 |
| Potassium Chloride | Potassium Chloride | 100 | 35 |
| Pioglitazone Hcl | Pioglitazone Hcl | 95 | 26 |
| Lansoprazole | Lansoprazole | 93 | 23 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 92 | 18 |
| Spironolactone | Spironolactone | 90 | 27 |
| Methenamine Hippurate | Methenamine Hippurate | 88 | 17 |
| Meloxicam | Meloxicam | 87 | 55 |
| Prednisone | Prednisone | 86 | 56 |
| Ibuprofen | Ibuprofen | 82 | 47 |
| Tizanidine Hcl | Tizanidine Hcl | 82 | 47 |
| Mirtazapine | Mirtazapine | 81 | 32 |
| Nifedipine Er | Nifedipine | 71 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 69 | 24 |
| Clonidine Hcl | Clonidine Hcl | 68 | 31 |
| Lactulose | Lactulose | 67 | 31 |
| Mupirocin | Mupirocin | 67 | 45 |
| Alogliptin | Alogliptin Benzoate | 66 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 65 | 37 |
| Celecoxib | Celecoxib | 64 | 26 |
| Loperamide | Loperamide Hcl | 64 | 28 |
| Entresto | Sacubitril/Valsartan | 63 | 13 |
| Irbesartan | Irbesartan | 61 | 19 |
| Atenolol | Atenolol | 60 | 19 |
| Ketoconazole | Ketoconazole | 60 | 25 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 59 | 37 |
| Amiodarone Hcl | Amiodarone Hcl | 56 | 17 |
| Insulin Aspart Flexpen | Insulin Aspart | 56 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 19 |
| Sertraline Hcl | Sertraline Hcl | 55 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | 16 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 49 | 49 |
| Pregabalin | Pregabalin | 49 | suppressed |
| Naproxen | Naproxen | 47 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | 13 |
| Insulin Aspart Prot Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 45 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 44 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 44 | 12 |
| Benzonatate | Benzonatate | 41 | 32 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | 11 |
| Levofloxacin | Levofloxacin | 41 | 37 |
| Clonazepam | Clonazepam | 40 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 17 |
| Theophylline Er | Theophylline Anhydrous | 40 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 39 | 24 |
| Nyamyc | Nystatin | 37 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | 13 |
| Azelastine Hcl | Azelastine Hcl | 35 | 17 |
| Digoxin | Digoxin | 35 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 35 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 27 |
| Estradiol | Estradiol | 34 | 22 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 34 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 34 | 14 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 33 | suppressed |
| Bumetanide | Bumetanide | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 28 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 30 | 11 |
| Dutasteride | Dutasteride | 30 | 13 |
| Lubiprostone | Lubiprostone | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 26 |
| Insulin Glargine Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 27 | 15 |
| Glimepiride | Glimepiride | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Dapagliflozin-Metformin Er | Dapaglifloz Propaned/Metformin | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 18 |
| Valsartan | Valsartan | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 23 | 16 |
| Ezetimibe | Ezetimibe | 23 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 21 | 13 |
| Metronidazole | Metronidazole | 21 | 15 |
| Repaglinide | Repaglinide | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Eliquis | Apixaban | 18 | suppressed |
| Levoxyl | Levothyroxine Sodium | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 17 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 14 | suppressed |
| Comfort Ez Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Nystatin | Nystatin | 14 | 12 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | 12 |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 13 | suppressed |
| Adefovir Dipivoxil | Adefovir Dipivoxil | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Acetic Acid | Acetic Acid | 11 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Insulin Degludec Pen (U-200) | Insulin Degludec | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $37.54 · 2 records | GlaxoSmithKline, LLC. | ImmunoCAP, SHINGRIX | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Shingrix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error